SEC Form 4 · accession 0001209191-19-018103
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Brynjelsen
Officer — President & CEO · Director
Period of report
Feb 20, 2019
Accepted (ET)
Mar 8, 2019 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001710340
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $7.31 | Feb 20, 2019 | A | 250,000 | A | — | Feb 19, 2029 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The shares subject to the option shall vest in 24 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2021.